Antiproliferative effect of rapamycin on growth factor-stimulated human adult lung fibroblasts in vitro may explain its superior efficacy for prevention and treatment of allograft obliterative airway disease in vivo.

[1]  G. Berry,et al.  Actuarial survival of heart-lung and bilateral sequential lung transplant recipients with obliterative bronchiolitis. , 1996, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[2]  M. B. King,et al.  Reproduction of the obliterative bronchiolitis lesion after heterotopic transplantation of mouse airways. , 1993, The American journal of pathology.

[3]  R. Morris,et al.  Rapamycin: FK506's fraternal twin or distant cousin? , 1991, Immunology today.